Objectives Worldwide, many infected individuals are unaware of their hepatitis B virus (HBV) status. We evaluated the effectiveness of HBV rapid testing in promoting linkage-to-care. Methods In 2012, volunteers were recruited from five Parisian centers. Participants were randomized 1 : 1 to receive standard serology (S) or rapid testing (VIKIA-HBsAg/Quick Profile anti-HBsAb) with confirmatory serology (R + S). The primary endpoint was percentage of individuals with appropriate linkage-to-care (nonimmunized individuals starting vaccination or HBsAg-positive individuals receiving medical evaluation). The secondary outcomes were percentage receiving HBV-test results and performance of HBV rapid tests. Results In total, 995 individuals were screened. Among the HBV-infection groups included in the primary endpoint (n = 409), 20 (4.9%) received appropriate linkage-to-care, with no difference between S and R + S groups (5.7 vs. 4.1%, P = 0.5). Two of eight HBsAg-positive participants had a medical visit (1/6 and 1/2 in the S and R + S groups, respectively) and 18/401 (4.5%) nonimmunized participants initiated . Factors that tended to be associated with linkage-tocare were female sex, birth country of high HBV prevalence, and extended medical stay. Test results were not obtained in 4.7% of participants, which was significantly higher in the S arm (P = 0.02). Both sensitivity and specificity were 100% for the VIKIAHBsAg rapid test and 94.4 and 80.8%, respectively, for the anti-HBsAb Quick Profile rapid test. Conclusion Despite a higher proportion of participants obtaining their results in the R + S arm and better performance of antiHBsAb rapid tests than described previously, we found no evidence that HBV screening based initially on rapid tests leads to increased HBV-vaccination rates or medical evaluation. This strategy should be evaluated in more hard-to-reach populations. Eur
Background
With more than 15 million infected individuals and 38 000 attributed deaths each year in the USA [1] and Europe [2] , hepatitis B virus (HBV) is one of the most frequent chronic infectious diseases, with a higher prevalence than HIV and hepatitis C virus (HCV) infection. More than two-thirds of HBV-infected individuals in Europe and the USA are unaware of their infection status [3, 4] . These individuals do not benefit from adequate medical care and constitute a reservoir of HBV transmission, which could be a source of new infections, such as the case for HIV [5] .
In France, HBV prevalence was estimated to be 0.65% in 2004, representing 281 000 individuals with positive hepatitis B surface antigen (HBsAg). In addition, 7.3%, or 3.2 million, were anti-hepatitis B core antibody (antiHBcAb) positive, indicating previous exposure to HBV [6] . Among chronic carriers of HBsAg, 55% (155 000) were unaware of their HBV status. Since 1994, France's HBV immunization policy has focused on two broad aims: identifying, testing, and vaccinating individuals at high risk of HBV exposure and vaccinating all individuals during infancy, childhood, or adolescence [7] . Despite these recommendations, vaccine coverage rates remained inadequate among infants until 2007 [7, 8] and were less than 50% in high at-risk groups [9] [10] [11] .
HBV testing is essential for several reasons. It confirms whether individuals have been vaccinated or effectively acquired anti-HBsAb, identifies individuals in need of HBV vaccination, and provides a gateway toward necessary care for infected patients, especially at early stages of disease [1] . A number of recommendations are currently available, with an emphasis on increased HBV testing and turnaround time in returning results [1, 4, 12] .
HBV tests are usually based on standard enzyme-linked immunosorbent assays (ELISA), which require long periods of time to process. With the recent development of HBV rapid tests, results with high sensitivity and specificity can be provided within minutes [13] . Consequently, tested patients would no longer need to collect their test results at a later time [14, 15] and more appropriate patient counseling could be provided at first consultation. However, no study to date has formally evaluated the effectiveness of rapid testing interventions as a means to increase linkageto-care among individuals unaware of their HBV status.
The main aim of the Optiscreen-B II study was to determine the usefulness of incorporating HBV rapid tests during screening to more adequately provide care for those tested. To this end, we conducted a randomized, multicenter trial determining whether appropriate care was provided when either rapid tests with confirmatory ELISA or standard ELISA were used.
Methods

Study design and participants
The Optiscreen-B II study was a multicenter, parallelgroup, randomized trial comparing the use of standard HBV tests with rapid tests. The study was approved by the Hôtel-Dieu Hospital Ethics Committee (Paris, France) in accordance with the Helsinki Declaration.
Volunteers were recruited from five study centers in the Paris metropolitan region, which actively participate in HBV screening, vaccination, and care -two sexually transmitted disease clinics, one primary healthcare center, one general screening center, and one travel clinic. From 29 February 2012 to 5 July 2012, participants were included if seeking care at any of the participating centers, were more than or equal to 18 years old, and could be available for further contact and medical follow-up at a single university teaching hospital.
Only individuals eligible for HBV screening were invited to participate. In a prerandomization phase, participants were asked questions on potential risk factors associated with HBV transmission during a face-to-face interview with a clinical research associate. This questionnaire [16] was based on screening/vaccination recommendations from the United States Centers of Disease Control and Prevention (CDC) [1] and the French council that determines immunization policies [17] . If a participant did not fulfill any one of the criteria recommending HBV testing, they were not included in the study. Second, as one major factor steering the decision to test in practice is complete certainty of previous HBV infection or vaccination status, participants with a confirmed HBsAg-positive, anti-HBsAb-positive, or anti-HBcAb-positive test (requiring irrefutable proof of result) were deemed ineligible for HBV screening.
Participants were not included if they were unwilling to participate, had already participated in the Optiscreen-B I validation study [13] , or were not covered under the national healthcare system. Signed written informed consent was obtained for all eligible participants before randomization.
Study interventions
Eligible participants were randomized 1 : 1 to receive one of two possible interventions: standard HBV test (S) or rapid HBV test with confirmatory ELISA (R + S). The central data management center (Inserm U707, Paris, France) was responsible for randomization. A computerized random number generator was used to select random permuted block sizes of 3 and 6 within each center. The randomization list was concealed from investigators, who assigned participants to testing groups through a web site after validating eligibility criteria.
In the S arm, ∼ 10 ml of blood was drawn and then tested for HBsAg, anti-HBsAb, and anti-HBcAb. Serostatus was determined using a commercially available ELISA assay (MONOLISA AgHBs Ultra, anti-HBs plus, anti-hepatitis B core antibody-anti-HBc-plus; Bio-Rad, Hercules, California, USA). Results were provided 7-14 days after testing and, depending on the study center, were either mailed to the participants or left at the study center for collection.
In the R + S arm, a 10 ml blood draw was collected. Before the blood sample coagulated, a few drops were immediately taken and applied to a rapid test determining HBsAg (VIKIA; Biomérieux, Marcy-L'Etoile, France) and anti-HBsAb status (Quick Profile; Lumiquick, Santa Clara, California, USA). Rapid tests were performed and interpreted according to the manufacturer's instructions by a trained clinical research associate as detailed previously [13] . Because of the poor sensitivity and negative predictive value of the rapid anti-HBsAb test [13] , the remaining blood sample was further tested using standard ELISA (as described in the S arm above). A presumptive diagnosis was made during the study visit on the basis of the results from the two rapid tests ( Table 1 ). All participants were asked to collect their ELISA results available 7-14 days after rapid testing.
For both arms, we established HBV-infection groups using ELISA results and defined them as follows: HBsAgpositive, resolved infection, isolated anti-HBc Ab + , vaccinated, and nonimmunized. Combination of results needed from a rapid test (R) and/or a serological test (S) to be considered as successfully obtaining test results. All participants listed as R did not necessarily need confirmation with ELISA (diagnosis from a rapid test was considered reliable). All participants listed as R + S required confirmation with ELISA (diagnosis from a rapid test was considered unreliable).
Study end-points
The primary outcome was the percentage of participants appropriately seeking care if needed. As this only applied to infection groups that required a medical intervention, analysis was restricted to HBsAg-positive and nonimmunized individuals. Considering that follow-up recommendations for isolated anti-HBcAb-positive patients were unclear [1, 18] , we decided not to evaluate the primary end-point in this HBV-infection group. However, the treating physician could recommend further evaluation. HBsAg-positive patients were provided instructions to schedule a comprehensive medical exam at Saint-Antoine Hospital, in accordance with European recommendations [19] . Appropriate care was then determined if a full evaluation of HBV disease was performed 6 months after screening. Nonimmunized individuals were contacted at most three times 4 to 6 months after screening through telephone by a clinical research associate. These participants were asked whether they had been vaccinated and, if so, the date of first HBV vaccination. Appropriate care was then determined if HBV vaccination was initiated between screening and the time of telephone interview. Participants who could not be contacted were considered nonvaccinated in analysis.
The secondary outcome was percentage of participants receiving their HBV-test result. For those study centers where HBV-test results were mailed, all participants were considered to have obtained their results (n = 567). For those centers where HBV-test results were not mailed out, participants were considered as receiving their result if they returned to the clinic to obtain printed results (S and R + S arms) or had a reliable rapid test result that did not necessarily require ELISA (R + S arm, Table 1 ). To evaluate the effect of bias from mailing results, we carried out a subgroup analysis including only centers where the test result was not mailed.
Statistical analysis
Power calculations were performed to detect more than 15% difference in immediate linkage-to-care and vaccination [20] . As almost no data were available before the start of this study, discussions from an expert panel of clinicians concluded that an estimated 30% of participants would have appropriate care with a standard HBV test. Assuming a type 1 error of 0.05 and 80% power, a minimum 152 participants for each group would be needed. As roughly 40% of the population would be either nonimmunized or HBsAg-positive from previous epidemiological studies [13] , a minimum of 375 participants for each group would be required.
Outcomes were compared using Pearson's χ 2 or Fisher's exact test. To understand the reasons for not obtaining HBV-test results and for seeking appropriate care, we used random-effects logistic regression to determine the univariable association between each outcome and a variety of demographic and HBV-transmission risk factors, while accounting for within-center correlation. Risk factors with a P-value of less than or equal to 0.2 in the univariate analysis and the study arm were retained and used to create a predictive, multivariable model.
In patients randomized to the R + S arm, we evaluated the performance of HBsAg and anti-HBsAb rapid tests compared with ELISA. Sensitivity, specificity, positive and negative predictive values (PPV and NPV, respectively), and area under the receiving operator characteristic curves were estimated for each rapid test, without taking into account indeterminate results.
All statistical analyses were carried out using STATA (version 12.1; StataCorp LP, College Station, Texas, USA) and significance was determined using a P-value less than 0.05. This trial is registered at ClinicalTrials.gov (NCT01767597). Figure 1 shows the flow of study participation. A total of 2061 participants were initially screened for eligibility, of whom 1000 (48.5%) were randomized to receive either S or R + S testing. Among these, five did not fully complete study intervention. Thus, a total of 995 participants were included in the analysis.
Results
Study participants
Half of the participants were men with an average age of 40.4 (SD = 15.8) years. A slight minority of participants were born in a country of intermediate or high HBVprevalence (HBsAg-positive 2.0-8.0%: n = 253, 25.4%; and HBsAg-positive > 8.0%: n = 175, 17.6%, respectively). Almost 6% of the participants lived in difficult social situations. No significant differences were observed between study groups (Table 2) , and yet, there was a higher proportion of participants who had received tattoos in the R + S than the S arm (P = 0.04).
HBV-infection status
Overall, there were eight participants with HBsAg-positive serology (R + S group: n = 2, S group: n = 6), yielding an HBsAg-positive prevalence of 0.8% (95% confidence interval: 0.3-1.6). All other participants had achieved resolution of infection (n = 124, 12.5%), isolated antiHBcAb (n = 34, 3.4%), were vaccinated (n = 428, 43.0%), or nonimmunized (n = 401, 40.3%). No difference was observed between randomization groups and HBVinfection status (P > 0.09).
Performance of HBsAg and anti-HBsAb rapid tests in the R + S arm Table 3 presents the classification probabilities of both rapid tests compared with standard serology for participants randomized to the R + S arm. While considering the very low prevalence of HBsAg-positive serology, the VIKIA rapid HBsAg test had perfect sensitivity, specificity, PPV, and NPV. While including only patients with definitive anti-HBsAb results from standard serology (N = 443), the Quick Profile anti-HBsAb test had high sensitivity, with moderately high specificity, PPV, and NPV.
Obtaining HBV test results
Of the 995 participants, 95.3% acquired their test results, whereas this proportion was fairly similar across HBVinfection groups (P = 0.15, Fig. 2 ). Among the participants Effectiveness of HBV rapid tests Bottero et al.
www.eurojgh.comincluded in centers where results were not mailed (n = 428), 381 (89.0%) received their HBV-test result, whereas a significant difference was observed between S and R + S groups (85.4 and 92.6%, respectively, P = 0.02).
In multivariable analysis (data not shown), the only significant risk factor associated with failure to obtain results was the S study arm after adjusting for age, parents from a country of high HBV prevalence, and HBV-infection status.
Appropriate care for HBV-infection groups in need of medical intervention
Among those HBV-infection groups in need of a medical intervention (n = 409), 20 (4.9%) received appropriate care, with no difference between study arms (P = 0.5, Fig. 2 ). Two of eight (25.0%) HBsAg-positive participants came for medical consultation to ascertain their HBVdisease status (1/6 and 1/2 in the S and R + S groups, respectively, P = 0.3) and 18 of 401 (4.5%) nonimmunized participants initiated HBV vaccination (11/205 and 7/196 in the S and R + S groups, respectively, P = 0.5). Even when excluding patients who could not be reached by telephone, there was no difference in the vaccination rates between S (n = 12, 6.6%) and R + S (n = 8, 4.9%) interventions (N = 346, P = 0.5).
In multivariable analysis (data not shown), men were borderline significantly less likely than women to receive appropriate HBV care (P = 0.05). Participants from high HBV-endemic countries and those who had an extended stay at a medical facility tended to receive more adequate care (P = 0.08 and 0.07, respectively). 
Discussion
To the best of our knowledge, this is the first randomized study that directly evaluates whether additional HBsAg and anti-HBsAb rapid testing has any benefit compared with confirmatory ELISA. There was a higher proportion of participants obtaining their results in the rapid testing arm, and yet, there was no evidence that rapid testing led to increased HBV vaccination rates or 'linkage-to-care'. Even though no clear determinant was observed for more appropriate care, tendencies were indeed noted with female sex, originating from a high HBV-endemic countries, and prolonged stay at a medical facility. Among HBsAg-positive participants, no association was observed between randomized groups and linkage-tocare. This finding could be attributed to the low prevalence of HBV infection, in particular, compared with a previous evaluation among individuals without national healthcare (0.8 vs. 2.1%, respectively) [21] . With higher HBsAg prevalence, the benefit of rapid testing would probably be more readily observed in specific subpopulations at risk for HBV infection (i.e. immigrants, intravenous drug users, men who have sex with men, etc.) [6, [21] [22] [23] , as has been suggested for HIV [24, 25] and/or HCV [26, 27] . The most notable of them are 'hard-to-reach' populations (i.e. those with difficult access to care). As all participants came to a medical center on their own initiative and were required to have some form of health insurance, individuals with barriers to healthcare were not well represented [6, [21] [22] [23] [24] [25] [26] [27] .
Rapid tests also failed to show any effect on HBVvaccination rates, which were largely inadequate [11, 28] . This finding might reflect a general problem with vaccination coverage in France [7] . However, it needs to be stressed that, as a major limitation, the Quick Profile antiHBsAb rapid test could not be used to confirm nonimmunized HBV status [13] . As this rapid test had poor sensitivity, a definitive result at the initial visit could not be provided to participants with a negative anti-HBsAb rapid test. This problem prevented us from providing appropriate counseling on HBV vaccination without resorting to serological testing, thus making it difficult to evaluate the potential impact of anti-HBsAb rapid testing. Unfortunately, no other alternative rapid test with high classification probabilities was available, specifically one that has been evaluated apart from the manufacturer [29] .
However, we did observe somewhat satisfactory performance of the anti-HBsAb rapid test, contrary to our earlier report [13] . The test used in our previous evaluation was a [30] and HCV infection [31] . In such a framework, specific steps of healthcare involvement, starting from identifying those infected by testing to those receiving adequate care, are evaluated at each level. In our study, we obtained encouraging findings on the proportion of participants receiving test results, thus enabling infected individuals to be identified. However, this effect depended on the reliability of rapid test results (i.e. no need to obtain serological results after rapid testing), which was less the case among nonimmunized individuals. The distribution of HBV status groups needs to be considered when comparing our results with others. In any case, infection awareness has provided a major step toward linkage-to-care in the past [32, 33] , and yet, there was a substantial drop-off in the proportion of patients adequately seeking care in our study. Further research would be needed to determine whether this finding is because of the low risk of HBV-related disease perceived by participants, laxness of HBV-related care by the physician, or a combination of both.
One limitation of our study relates to the conditions under which serological results were obtained. Blood samples were immediately drawn after the study visit, contrary to routine practice, where participants would have to test at a clinical laboratory located at a different facility. This may have increased the proportion of patients obtaining HBV test results. Second, participants could have had a strong preference to receive rapid testing and, when allocated to the S arm, would have been disappointed and even less likely to obtain screening results. However, such a bias, likely to favor the R + S arm, appeared to be minimal, considering that no difference between randomized arms was observed.
Notwithstanding these limitations, our study provides novel insight into the use of rapid tests during routine care. This is the first study to evaluate the clinical impact of adding rapid testing by randomizing participants to a specific intervention, while at the same time, we used a composite endpoint reflecting healthcare interventions that affect both the individual (i.e. protection against HBV infection, assessing the need for HBV-specific care) and the population (i.e. vaccination coverage). Finally, we show the complexity of evaluating interventions conditional on the status of HBV infection, which should be considered in future testing campaigns.
Conclusion
In conclusion, rapid testing for HBV with confirmatory ELISA might not increase vaccination for nonimmunized and linkage-to-care for infected individuals compared with standard practice. However, the lack of reliable antiHBsAb tests may have compromised any advantage with rapid testing, stressing the usefulness of tests with higher sensitivity and specificity in identifying nonimmunized individuals. Furthermore, rapid testing should be evaluated in populations with higher HBsAg seroprevalence. Considering that these individuals are also at high risk of exposure to HIV and HCV, algorithms incorporating simultaneous rapid testing for these viruses are warranted. 
